Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder Cancer
Pathology International · 2025
DOI: 10.1111/pin.70002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, 2025. Verfasst von Takahisa Yamashita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of pathology, Saitama Medical Center, Saitama Medical University, kawagoe, Saitama, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Histone Deacetylase 1, BCG Vaccine, Nanog Homeobox Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: This study was supported by the Suzuki Urological Research Foundation 2023 (T.Y.)..
Abstract (Originalsprache)
Urinary bladder cancer includes non‐muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). While patients with NMIBC have a better prognosis, NMIBC often recurs, requiring long‐term surveillance and repeated treatments. Intravesical Bacillus Calmette‐Guérin (BCG) therapy is standard for high‐grade or recurrent NMIBC; however, 30%–50% of patients failed to respond, and the mechanisms of resistance remain unclear. To identify predictive biomarkers for response to intravesical BCG therapy, we analyzed NANOG and Histone deacetylase 1 (HDAC1) expression in 90 bladder cancer specimens from NMIBC patients treated with BCG therapy using immunohistochemistry. The correlation between NANOG and HDAC1 expression and clinical outcomes, including response to BCG therapy, was assessed. High‐grade NMIBC cases showed significantly higher expression of NANOG and HDAC1 compared to low‐grade cases ( p < 0.05). Additionally, elevated NANOG expression in combination with HDAC1, was associated with poor response to BCG therapy and decreased lymphocyte infiltration in the tumor‐microenvironment. NANOG is suggested to directly increases HDAC1 expression, which could suppress lymphocyte infiltration in the tumor microenvironment by altering immune‐related gene expression. These findings suggest that the NANOG/HDAC1 axis plays a key role in predicting resistance to intravesical BCG therapy in NMIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of pathology, Saitama Medical Center, Saitama Medical University, kawagoe, Saitama, Japan.
Förderung
- This study was supported by the Suzuki Urological Research Foundation 2023 (T.Y.).
Zitieren
APA
Yamashita, T., Higashi, M., Yamazaki, M., Imada, H., Takayanagi, N., Shimizu, T., Sawada, K., Yamamoto, W., Murakami, C., Nagata, M., Kikuchi, Y., & Momose, S. (2025). Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder Cancer. Pathology International. https://doi.org/10.1111/pin.70002
Vancouver
Yamashita T, Higashi M, Yamazaki M, Imada H, Takayanagi N, Shimizu T, et al. Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder Cancer. Pathology International. 2025. doi:10.1111/pin.70002
BibTeX
@article{Yamashita2025,
author = {Yamashita, Takahisa and Higashi, Morihiro and Yamazaki, Mami and Imada, Hiroki and Takayanagi, Natsuko and Shimizu, Tomomi and Sawada, Keisuke and Yamamoto, Wataru and Murakami, Chiaki and Nagata, Marino and Kikuchi, Yukina and Momose, Shuji},
title = {Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder Cancer},
journal = {Pathology International},
year = {2025},
doi = {10.1111/pin.70002}
}
EUVIMED